home / stock / lexxw / lexxw news

LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 07/15/21

Stock Information
Company Name: Lexaria Bioscience Corp. Warrant
Stock Symbol: LEXXW
Market: NASDAQ
Website: lexariabioscience.com
Menu
LEXXW LEXXW Quote LEXXW Short LEXXW News LEXXW Articles LEXXW Message Board
Get LEXXW Alerts

News, Short Squeeze, Breakout and More Instantly...
LEXXW - Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council

VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce results f...
LEXXW - InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced an additional expansion of its intellectual property (“IP”) portfolio with its first-ever patent granted in Japan. According to the update, “Stable ready-to-d...

LEXXW - Lexaria Receives Patent Protection in Japan

(TheNewswire) New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia Kelowna, British Columbia, July 13, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company ...

LEXXW - Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily d...
LEXXW - Lexaria Announces 2021 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting'). On June 28, 2021 at 1:00 p.m. (Pacific Time)...

LEXXW - Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

(TheNewswire) DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 Kelowna, British Columbia - TheNewswire - June 15, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) ...

LEXXW - Lexaria Provides Progress Report on Six R&D Programs

All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strategic partnerships KE...
LEXXW - Lexaria Announces Issuance of Options

(TheNewswire) Kelowna, British Columbia – TheNewswire – June 8, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global ...

LEXXW - Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria's Patented Technology for Hypertension Relief Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation Second Human Clinical Study, Hyper-H21-2, To Commence Immediat...

LEXXW - Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SAR...
Previous 10 Next 10